United Therapeutics Reports Record 2025 Revenue, Double-Digit Growth, Positive Outlook
UTHR sits 77% above its 52-week low of $266.98.
Summary
United Therapeutics announced strong financial results for Q4 and full year 2025, with record revenues and double-digit growth in both revenue and diluted EPS, driven by key product sales and a positive outlook for clinical programs.
Key Events · Earnings and Guidance · UTHR
-
Record Full Year 2025 Revenues
United Therapeutics reported record total revenues of $3.18 billion for 2025, an 11% increase over the previous year.
-
Double-Digit EPS Growth
Diluted earnings per share rose by 13.1% to $27.86 for the full year 2025.
-
Strong Tyvaso DPI Sales
Tyvaso DPI sales grew by 25% to $1.29 billion, contributing significantly to overall product revenue growth.
-
Positive Clinical Pipeline Outlook
Management anticipates "transformational growth" from upcoming pivotal data from ADVANCE OUTCOMES and TETON-1 clinical programs.
Analysis · UTHR · Life Sciences
This 8-K details the strong financial results for 2025, which were also reported in a concurrent 10-K filing. United Therapeutics achieved record revenues and double-digit growth in both revenue and diluted EPS, primarily driven by the robust performance of its Tyvaso DPI product. Management's optimistic outlook, including expectations for continued double-digit revenue growth and potential "transformational growth" from upcoming clinical trial data, signals a positive future. The significant reduction in litigation accruals and ongoing share repurchases further enhance the company's financial position and investor appeal.
At the time of this filing, UTHR was trading at $473.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.4B. The 52-week trading range was $266.98 to $519.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.